Mr. Smith brings more than 30 years of biotechnology and pharmaceutical industry experience to the Refuge board of directors. He recently retired from Celgene, where he held multiple positions over a ten year tenure culminating in an appointment as president and chief operating officer. He previously held leadership positions in inflammation and immunology, guiding growth of the franchise from 13 people to more than 1,300 worldwide. He oversaw the clinical development, global registration and commercial success of the blockbuster drug Otezla and worked closely with Juno post acquisition to integrate the capabilities of cellular immunotherapy into Celgene. Mr. Smith’s prior experience at Pharmacia (acquired by Pfizer) and at Biovail included global responsibility for sales and marketing, creating and executing commercial and business development strategies and contributing to regulatory and clinical development strategies. Mr. Smith also serves on the board of directors of Titan Pharmaceuticals, Triumvira Immunologics and Springbank Pharmaceuticals. Mr. Smith received both his bachelor’s degree in chemistry and biology and his honours bachelor’s degree in pharmacology and toxicology from the University of Western Ontario, and his masters of international business management from the American Graduate School of International Management (Thunderbird).